sarilumab

Why 2016 drug approvals fell
Why 2016 drug approvals fellWhile FDA approved far fewer new drugs in 2016 than 2015, the agency quickly approved novel and breakthrough therapies.
New rheumatoid arthritis therapies are comingFour new drugs and a biosimilar should be on your radar.
Sarilumab effective in broad range of RA patients: StudySarilumab, an investigational, human antibody against the IL-6 receptor, is highly effective in the difficult-to-treat TNF-IR population in rheumatoid arthritis (RA), according to data presented during the American College of Rheumatology (ACR) Annual Meeting in San Francisco, California.
IL-6 inhibitor shows positive clinical benefit in RA patientsSarilumab may be an effective option for patients with moderately-to-severely active rheumatoid arthritis (RA) according to topline results from a new study.
EULAR: Sarilumab investigational anti-IL-6R therapy shows positive results in rheumatoid arthritis treatment in studySanofi and Regeneron Pharmaceuticals presented positive results from a phase 3 trial of investigational drug sarilumab in rheumatoid arthritis (RA) patients who were inadequate responders to methotrexate (MTX) therapy at the European League Against Rheumatism Annual Congress (EULAR 2014) Congress in Paris, France.